As the Trump administration pushes for drug price transparency, the pharmaceutical industry is already trying to subvert the coming changes.
On a Monday morning press call, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl said they believe “just including list prices is not sufficient and would be misleading for several reasons.” He contends that since list prices rarely reflect what consumers actually pay through insurance, the price information could discourage patients from seeking needed medical attention.
Instead, PhRMA wants to provide in-ad links to websites that would reportedly feature a “drug’s list price, an expected range of possible patient out-of-pocket costs and financial support that is available to help consumers pay for their drugs.”
PhRMA’s move did not impress Health and Human Services (HHS) Secretary Alex Azar, who does not believe this half-measure is nearly enough:
More here
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
2 comments:
Getting Big Pharma under control is like herding cats.
Should increase requirements / regulations. They only produce toxic addictive drugs and not ones that help but can be stopped. Worst than opioids.
Post a Comment